A Milestone Moment: FDA Approves Addyi® for Hypoactive Sexual Desire Disorder in Postmenopausal Women
December 17, 2025
Brand Name :
Equioxx, Previcox, PrevEquine, Firox
Synonyms :
firocoxib
Class :
NSAIDs
Dosage Forms & Strengths
Tablets
57mg
Chewable tablets
57mg
227mg
Oral paste
0.1mg/kg
Only for veterinary use
Horses
0.1mg/kg (or) 0.045mg/lb (oral paste) orally one time a day for two weeks
(or)
57mg (tablet) orally one time a day for two weeks to horses of 800-1300lbs weight
Dogs
5mg/kg orally one time a day
Orthopaedic and soft-tissue surgery
5mg/kg orally one time a day prior to initiation of surgery and continue for two days
the rate of decrease of abacavir may be reduced
the risk of hemorrhage and bleeding may be increased
the antihypertensive activity of acebutolol may be reduced
the risk of adverse effects may be increased
the risk of adverse effects may be increased
the risk of nephrotoxicity may be increased
the rate of excretion of allopurinol may be reduced
the risk of bleeding may be increased
the rate of excretion may be reduced
the rate of excretion may be reduced
the risk of gastrointestinal bleeding may be reduced
the risk of hypertension may be increased
the risk of hyperkalemia may be increased
the risk of gastrointestinal bleeding may be increased
the risk of hyperkalemia may be increased
Actions and spectrum:
Firocoxib is a non-steroidal anti-inflammatory drug that functions as a COX-2 inhibitor
Frequency not defined
Ulcers of gums, lips, tongue
Erosions of face
Diarrhea
Pruritis
Colic
Otitis
Black Box Warning
For veterinary use only
Never administer concurrently with corticosteroids
Not for human use
Contraindication/Caution:
Contraindication:
Hypersensitivity
Cardiovascular dysfunction
Hepatic dysfunction
Gastrointestinal toxicity
Pregnancy consideration in animals:
Safety and efficacy data are not established
Lactation:
Safety and efficacy data are not established
Pregnancy category:
Category A: Studies that were well-controlled and met expectations revealed no risk to the fetus `in either the first or second trimester.
Category B: There was a lack of studies on pregnant women and no evidence of risk to the fetus in animal experiments.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence, these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Pharmacology:
Firocoxib is an anti-inflammatory drug intended for veterinary use
Pharmacodynamics:
It is an inhibitor of cyclooxygenase
Pharmacokinetics:
Absorption
Absorbed rapidly upon oral administration
The average peak concentration (Cmax) is 75.3± 21.5 ng/ml
Distribution
97% of firocoxib is protein bound, i.e., plasma proteins
Metabolism
Undergoes metabolism in the liver by glucuronidation and dealkylation
Elimination and excretion
Primarily excreted in urine (animal excreta), small portions of firocoxib are known to undergo biliary excretion
Half-life:
38.7± 7.8 hours
Administration:
To be used in dogs and horses as advised by the veterinarian
Patient information leaflet
Generic Name: firocoxib
Why do we use firocoxib?
Firocoxib is an NSAID indicated for use in the management of pain and inflammation due to OA (osteoarthritis) in horses and postoperative pain in dogs, along with treating osteoarthritis.